SRPT has been in the news 750% more than usual
May 09, 2025, 12:32 PM
17.96%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
SRPT has been in the news recently: Sarepta Therapeutics, Inc. reported a first-quarter loss of $3.42 per share in 2025, significantly missing the analyst estimate of a 95-cent loss. This financial setback highlights ongoing challenges for the company amid broader market trends and economic concerns.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.